Mangoceuticals (MGRX) Non-Current Debt (2022 - 2026)
Mangoceuticals' (MGRX) quarterly Non-Current Debt came in at $44944.0 in Q2 2026, down 42.57% quarter-over-quarter from $78260.0 in Q4 2022.
Powered by 
Analysis
Mangoceuticals (MGRX) Non-Current Debt (2022 - 2026) Analysis & Trends
Mangoceuticals has disclosed Non-Current Debt across 2 years of filings, most recently posting $44944.0 for Q2 2026.
- In Q2 2026, Non-Current Debt changed N/A year-over-year to $44944.0; the TTM figure through Jun 2026 stood at $44944.0 (changed N/A YoY), while the FY2022 annual figure was $78260.0, changed N/A from the prior year.
- Non-Current Debt came in at $44944.0 for Q2 2026 at Mangoceuticals, down from $78260.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $78260.0 in Q4 2022 to a low of $44944.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Hinge Health | 7.41 Bn | 7.03 Bn | 183.95 Mn | - |
| 2 | Hims & Hers Health | 6.47 Bn | 5.63 Bn | 480.80 Mn | - |
| 3 | Ethos Technologies | 2.54 Bn | 2.37 Bn | 185.54 Mn | - |
| 4 | Omada Health | 1.38 Bn | 1.16 Bn | 63.79 Mn | - |
| 5 | Teladoc Health | 1.14 Bn | 366.41 Mn | 416.09 Mn | - |
| 6 | Talkspace | 870.58 Mn | 779.48 Mn | 24.80 Mn | - |
| 7 | Akso Health | 259.44 Mn | 259.25 Mn | - | - |
| 8 | LifeMD | 147.29 Mn | 147.29 Mn | - | - |
| 9 | eHealth | 31.71 Mn | -69.34 Mn | - | 114.61 Mn |
| 10 | Mangoceuticals | 7.39 Mn | 7.14 Mn | 44,215.00 | 44,944.00 |